P
Prothena Corporation plc (PRTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$7.97
-0.19 (-2.33%)
Market Cap: $419.01M
Last updated: Nov 17, 2026 at 11:06 AM ET
Prothena Corporation plc (PRTA) Valuation Multiples
Prothena Corporation (PRTA) trades at 7.8x sales and 1.5x book value. Its P/S of 7.8x is below its 5-year median of 11.8x. Its forward P/E is 33.9x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 33.9x |
| Price to sales | 7.8x |
| Price to book | 1.5x |
| PEG | N/A |
| FCF yield | -7.8% |
Historical Medians
Against its 10-year medians, its P/S is 84.1% below 49.1x and its P/B is 31.8% below 2.2x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 7.8x | 11.8x | 49.1x |
| P/B | 1.5x | 2.2x | 2.2x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 5.5x in 2024 to 775.6x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $9.55 | N/A | 53.1x | 1.8x |
| 2024 | $13.85 | N/A | 5.5x | 1.5x |
| 2023 | $36.34 | N/A | 21.3x | 3.5x |
| 2022 | $60.25 | N/A | 59.7x | 5.2x |
| 2021 | $49.40 | 45.3x | 11.1x | 4.9x |
| 2020 | $12.01 | N/A | 562.0x | 2.6x |
| 2019 | $15.83 | N/A | 775.6x | 2.3x |
| 2018 | $10.30 | N/A | 426.7x | 1.3x |
| 2017 | $37.49 | N/A | 51.8x | 3.5x |
| 2016 | $49.19 | N/A | N/A | 4.7x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PRTA
What is PRTA's forward P/E ratio?
Prothena Corporation has a forward P/E ratio of 33.9x.
Is PRTA stock overvalued?
GNG's valuation label for PRTA is Fairly valued.
What is PRTA's price to sales ratio?
Prothena Corporation has a price to sales ratio of 7.8x.
PRTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors